key: cord-1044735-8zsw866s authors: Duployez, Claire; Le Guern, Rémi; Tinez, Claire; Lejeune, Anne-Laure; Robriquet, Laurent; Six, Sophie; Loïez, Caroline; Wallet, Frédéric title: Panton-Valentine Leukocidin–Secreting Staphylococcus aureus Pneumonia Complicating COVID-19 date: 2020-08-03 journal: Emerg Infect Dis DOI: 10.3201/eid2608.201413 sha: 65e438f9d2fef48a118656b9e114d5f7fc259241 doc_id: 1044735 cord_uid: 8zsw866s Necrotizing pneumonia induced by Panton-Valentine leukocidin–secreting Staphylococcus aureus is a rare but life-threatening infection that has been described in patients after they had influenza. We report a fatal case of this superinfection in a young adult who had coronavirus disease. produced by some strains of Staphylococcus aureus. These strains are responsible for primary skin infections and necrotizing pneumonia. This rare entity is mainly described in young immunocompetent patients with an influenza-like prodrome and has a high case-fatality rate (1, 2) . We report a case of necrotizing pneumonia induced by PVL-secreting methicillin-susceptible S. aureus in a patient infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and who had coronavirus disease . In March 2020, during the SARS-CoV-2 outbreak in France, a man in his 30's who had no underlying conditions came to an emergency department because of fever, cough, and blood-streaked sputum that developed for 3 days. A diagnosis of pleuropneumonia was made, and antimicrobial therapy was initiated with cefotaxime plus metronidazole. Test results for Streptococcus pneumoniae and Legionella pneumophila serotype 1 urinary antigens were negative. A reverse transcription PCR specific for respiratory viruses also showed negative results. The next day, further respiratory deterioration required transfer of the patient to an intensive care unit (ICU) for intubation, mechanical ventilation, and inotropic support. Spiramycin was added to the previous drug regimen. Chest computed tomography showed a parenchymal consolidation of the left Necrotizing pneumonia induced by Panton-Valentine leukocidin-secreting Staphylococcus aureus is a rare but lifethreatening infection that has been described in patients after they had influenza. We report a fatal case of this superinfection in a young adult who had coronavirus disease. upper lung without ground-glass opacities commonly described for COVID-19 (3). Four days after intubation, the condition of the patient had not improved. We performed a reverse transcription PCR specific for SARS-CoV-2 on an endotracheal aspirate by using the method developed by the National Reference Centre for Respiratory Viruses (Institut Pasteur, Paris, France). The PCR result was positive for SARS-CoV-2 (4). Chest computed tomography showed worsening of bilateral parenchymal damage with complete consolidation of the left lung, cavitary lesions suggestive of multiple abscesses, and appearance of areas of ground-glass opacities in the right lung ( Figure) . The chest radiograph also showed a left pleural effusion. Bacteriological analysis of pleural drainage showed gram-positive cocci; the culture yielded monomicrobial S. aureus, which was identified by using matrix-assisted laser desorption/ionization time-offlight mass spectrometry (Bruker Daltonics, https:// www.bruker.com). The bacterial strain was resistant only to penicillin G (VITEK 2 System; bioMérieux, https://www.biomerieux.com). Because of this necrotizing pneumonia associated with acute respiratory distress syndrome, a PVL-producing strain was suspected. We confirmed PVL production by using a specific PCR as described by Deurenberg et al. (5) . We changed antimicrobial drug therapy to oxacillin plus clindamycin (for antitoxin effect) against methicillin-susceptible S. aureus and lopinavir/ritonavir (quickly stopped because of suspected toxicity) plus azithromycin against SARS-CoV-2. Three days later, given a lack of clinical improvement, antimicrobial therapy was changed to piperacillin/tazobactam plus linezolid (for antitoxin effect). Bronchoscopy showed that the left bronchial tree was obstructed by purulent secretions. Because of deterioration of respiratory, renal, and liver functions, venovenous extracorporeal membrane oxygenation and anticoagulation were initiated 10 days after ICU admission. Two days later, we performed upper left lobectomy, and antimicrobial drug therapy was incremented with meropenem, gentamicin, and linezolid. However, the patient died 17 days after his admission to the hospital. PVL-secreting S. aureus necrotizing pneumonia is frequently preceded by an influenza-like infection (6), which might be a possible causative factor. Influenza virus is known to impede phagocytic killing and damage the bronchial epithelium, thus reducing secretin clearance and facilitating bacteria adhesion (2) . It also induces an influx of immune cells to lung tissues, including neutrophils; the rapid killing of these cells by PVL and release of inflammatory mediators might promote disease development by damaging the epithelium (7, 8) . The association of PVL-secreting S. aureus and influenza virus has been reported (6, 9) . We report a PVL-secreting S. aureus superinfection in a patient who had COVID-19. Our findings indicate that the new SARS-CoV-2 is, in the same way, a facilitating factor for PVL-producing S. aureus necrotizing pneumonia. In 2003, during the SARS-CoV outbreak, an increase in S. aureus superinfection (mostly methicillinresistant S. aureus ventilator-acquired pneumonia) was described. Given common points between SARS-CoV-2 and previous coronaviruses, Lupia et al. discussed this issue for COVID-19 and suggested consideration of methicillin-resistant S. aureus coverage to reduce the risk of superinfection (10) . In PVL-producing S. aureus superinfection, prescribing antimicrobial drugs that have an antitoxin effect, such as clindamycin or linezolid, remains essential (2) . Thus, in previously healthy young adults admitted to an ICU for COVID-19 and S. aureus superinfection, a PVL-producing strain should be assumed and treatment provided accordingly. Dr. Duployez is a microbiologist at Centre Hospitalier Universitaire Lille, Lille, France. Her primary research interest is medical diagnosis of bacterial diseases. C oronavirus disease (COVID-19), caused by severe acute respiratory syndrome coronavirus 2, has been extensively reported since the outbreak in Wuhan, China, and can progress to involve major respiratory complications (1). Patients commonly have fever, cough, abdominal pain, and diarrhea. During the second week of illness, decompensation occurs in some patients, possibly driven by the cytokine storm associated with increased levels of interleukin-6. We report 3 case-patients with COVID-19 who were improving after successful treatment during the critical period but showed development of pulmonary emboli (PEs) despite deep vein thrombosis (DVT) prophylaxis. Three patients admitted to Northwell Plainview Hospital (Plainview, NY, USA) showed positive results for COVID-19 and had acute hypoxic respiratory failure secondary to COVID-19. All 3 patients received azithromycin and hydroxychloroquine, but their conditions continued to progress to more severe respiratory failure. During what was assumed to be the cytokine storm phase, on the basis of laboratory parameters and an increasing requirement for oxygen, the patients received intravenous steroids (solumedrol, 1-2 mg/kg/d for 5-8 d) and the interleukin-6 receptor antagonist tocilizumab (400 mg We report 3 patients with coronavirus disease who had a decline in respiratory status during their hospital course that responded well to intravenous steroids and interleukin-6 receptor antagonist therapy. These patients later showed development of persistent hypoxia with increased levels of d-dimer levels and were given a diagnosis of pulmonary embolisms. Association between Staphylococcus aureus strains carrying gene for Panton-Valentine leukocidin and highly lethal necrotising pneumonia in young immunocompetent patients Communityacquired necrotizing pneumonia due to methicillin-sensitive Staphylococcus aureus secreting Panton-Valentine leukocidin: a review of case reports COVID-19) outbreak: what the Department of Radiology should know Investigation Team. First cases of coronavirus disease 2019 (COVID-19) in France: surveillance, investigations and control measures Rapid detection of Panton-Valentine leukocidin from clinical isolates of Staphylococcus aureus strains by real-time PCR Epidemiology of post-influenza bacterial pneumonia due to Panton-Valentine leucocidin positive Staphylococcus aureus in intensive care units: a retrospective nationwide study Combined action of influenza virus and Staphylococcus aureus Panton-Valentine leukocidin provokes severe lung epithelium damage Pathogenesis of Staphylococcus aureus necrotizing pneumonia: the role of PVL and an influenza coinfection Successful management of Panton-Valentine leukocidinepositive necrotising pneumonia and A/H1N12009 influenzavirus coinfection in adult novel coronavirus (2019-nCoV) outbreak: a new challenge